De-escalation of IBD Therapy: When, Who, and How?

被引:5
|
作者
Waljee, Akbar K. [1 ,2 ,3 ]
Chaisidhivej, Natapat [4 ]
Saini, Sameer D. [1 ,2 ,3 ]
Higgins, Peter D. R. [3 ]
机构
[1] VA Ctr Clin Management Res, Ann Arbor, MI USA
[2] Univ Michigan, Med Sch, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Sch Med, Dept Internal Med, Div Gastroenterol & Hepatol, Ann Arbor, MI USA
[4] Mahidol Univ, Bangkok, Thailand
关键词
D O I
10.1093/crocol/otz008
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
When patients with inflammatory bowel disease reach clinical remission with biologic therapy, a question that often comes up is, "when can I stop my biologic medication?" This is a question fraught with challenges for both physicians and patients. For physicians, there are valid concerns that stepping down from a successful therapy will lead to relapse and disease exacerbation, and that stepping down could lead to anti-biologic antibodies. For patients, the question is often driven by concerns about long-term side effects and costs of biologics. This review provides an overview of the rationale for, and risks of, withdrawal of IBD therapy. Selected studies have shown how to identify subsets of patients in whom de-escalation can be performed with low risk of relapse. Practical guidance on when and how to de-escalate IBD therapy is provided.
引用
收藏
页数:5
相关论文
共 50 条
  • [41] De-escalation of commitment in software projects: Who matters? What matters?
    Heng, CS
    Tan, BCY
    Wei, KK
    INFORMATION & MANAGEMENT, 2003, 41 (01) : 99 - 110
  • [42] PATIENTS WITH ULCERATIVE COLITIS WHO HAVE NORMALIZED HISTOLOGY ARE CLINICALLY STABLE AFTER DE-ESCALATION OF THERAPY
    Akiyama, Shintaro
    Traboulsi, Cindy
    Silfen, Alexa
    Rodriguez, Tina
    Rai, Victoria
    Erondu, Amarachi
    Shaffer, Seth R.
    Christensen, Britt
    Rubin, David T.
    GASTROENTEROLOGY, 2021, 160 (06) : S173 - S174
  • [43] Antiplatelet Therapy After PCI: The Art and Science of De-Escalation
    Storey, Robert F.
    CIRCULATION, 2024, 149 (08) : 601 - 604
  • [44] Potential for Cefazolin as De-escalation Therapy for Klebsiella Pneumoniae Bacteraemia
    Ng, Tat Ming
    Teng, Christine B.
    Lew, Ee Ling
    Ling, Li Min
    Ang, Brenda
    Lye, David C.
    ANNALS ACADEMY OF MEDICINE SINGAPORE, 2015, 44 (12) : 571 - 574
  • [45] ANTIBIOTIC DE-ESCALATION IN THE INTENSIVE THERAPY UNIT- A REVIEW
    Sharma, Jyoti
    Kosey, Sourabh
    Kumar, Raj
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH, 2016, 7 (09): : 3596 - 3601
  • [46] PATIENT ATTITUDES REGARDING CONTINUATION AND DE-ESCALATION OF BIOLOGIC THERAPY
    Kim, Emilie Soyeon
    Kumar, Anand
    Kozan, Philip
    Meira, Abramowitz
    Jacob, Vinita
    Scherl, Ellen J.
    Longman, Randy S.
    Battat, Robert
    Lukin, Dana J.
    GASTROENTEROLOGY, 2020, 158 (06) : S436 - S437
  • [47] Shortening and De-Escalation of Dual Antiplatelet Therapy After PCI
    Voudris, Konstantinos V.
    Feldman, Dmitriy N.
    CURRENT TREATMENT OPTIONS IN CARDIOVASCULAR MEDICINE, 2023, 25 (05) : 127 - 141
  • [48] Shortening and De-Escalation of Dual Antiplatelet Therapy After PCI
    Konstantinos V. Voudris
    Dmitriy N. Feldman
    Current Treatment Options in Cardiovascular Medicine, 2023, 25 (5) : 127 - 141
  • [49] De-escalation in DCIS Care
    Nash, Amanda L. L.
    Wang, Sabrina
    McDuff, Susan
    Hwang, E. Shelley
    CURRENT BREAST CANCER REPORTS, 2023, 15 (01) : 58 - 68
  • [50] De-escalation of adjuvant radiotherapy
    Gourd, Katherine
    LANCET ONCOLOGY, 2021, 22 (12): : 1657 - 1657